Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for ...

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and ...

Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human ...

Viatris Inc.  today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The ...

The year is ending with a strong flow of clinical results, with Percheron Therapeutics due to release key trial data tomorrow ...

Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders ...

Favezelimab (MK-4280) is an investigational anti-lymphocyte activation gene-3 (LAG-3) antibody. LAG-3 is a cell surface immunomodulatory receptor expressed on various immune cells that down-regulates ...

Liver fibrosis is characterized by the excessive accumulation of extracellular matrix components, leading to scarring and impaired liver function. Traditionally linked to viral infections, alcohol ...

Dan G. Duda, DMD, Ph.D., of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at ...

The new promising data presented by Martin Forster, M.D., Ph.D., at the ESMO Immuno-Oncology (IO) Annual Congress 2024 ...

Monash University-led research is unlocking new ways for immunotherapy to better target cancer. Cancer immunotherapy has revolutionised treatment for patients, whereby the body’s own immune system is ...

The eyes have long been regarded as "immune-privileged" organs. Immunological system of ocular tissues prevents or resolves ...